Article stating that based on real world data, the value of rituximab maintenance in follicular lymphoma is limited and, in the absence of clear overall survival benefits, remains a controversial approach.
Home / Resource Library / Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma